A new test for bowel cancer could reduce the number of patients referred for endoscopy, says a new research. The test called as fecal immunochemical test (FIT) looks for hidden blood in the stool, which can be an early sign of bowel cancer.
According to the study, if doctors used the test, they could reduce the number of patients needing to go to hospital for an endoscopy by almost a third. Endoscopy is a procedure where a thin tube is used to examine the bowel.
Improved Combination Therapies for Bowel Cancer Approaching Reality
Molecular link between chronic inflammation and DNA methylation, a process that slams cancer-fighting genes, expected to result in better combination therapies to treat and prevent colorectal cancer.
Advertisement
‘The fecal immunochemical test (FIT) test is much easier to use and more accurate and experts hope it will lead to more cases of bowel cancer being detected.
’
Tweet it Now
Studies have shown that between 60% and 80% of patients referred to hospital for endoscopy turn out not to have a serious bowel disease, including bowel cancer.
Dr Sjoerd Elias, from the University Medical Centre in Utrecht in the Netherlands, who led the study, said, "The amount of patients that are unnecessarily referred for an endoscopy strains health care budgets and exposes patients to a small but realistic risk from endoscopy associated complications.
![Benefit from Avastin in Bowel Cancer Could be Predicted by Protein Levels]( "Benefit from Avastin in Bowel Cancer Could be Predicted by Protein Levels")
Until now there has been no way of predicting the benefit of Avastin, or Bevacizumab, in bowel cancer although it has been shown to increase survival.
"Our study found that using a test called FIT, which detects the presence of haemoglobin in the patient's faeces, alongside the usual diagnostic work done by GPs could rule out nearly a third of patients from requiring an endoscopy to check for (serious bowel disease)."
The study looked at results for 810 patients from 266 GP practices in the Netherlands. Out of the 810 patients referred for an endoscopy, 669 were found to have no serious bowel disease.
The researchers found that about 30% of these patients could have been prevented from having an endoscopy. However, the researchers did point out that there was a small risk some patients with bowel cancer could be missed by using FIT.
The authors said careful monitoring for persistent symptoms would be needed, and may result in a delay in diagnosis for some patients. The FIT test is being rolled out in the UK over the next few years and is much simpler than the current fecal occult blood (Fob) test.The Fob test involves collecting six small samples of feces over a few days and posting them to a screening center.
The FIT test is much easier to use, requiring just one sample that is collected with a brush and then put into a small tube of liquid. It is also more accurate and experts hope it will lead to more cases of bowel cancer being detected.
Dr Anne Mackie, director of programmes for the UK National Screening Committee, managed by Public Health England, said, "The new FIT test, which will be rolled out in the English Bowel Cancer Screening Programme over the next few years, will make it easier for people to get checked for risk of bowel cancer - as early diagnosis and treatment can save lives.
"PHE has already started looking into the logistics of introducing FIT and is keen to see this new improved kit fully available as soon as possible."
The study is published in the journal BMC Medicine.
Source: Medindia
Benefit from Avastin in Bowel Cancer Could be Predicted by Protein Levels
Until now there has been no way of predicting the benefit of Avastin, or Bevacizumab, in bowel cancer although it has been shown to increase survival.
Advertisement
"Our study found that using a test called FIT, which detects the presence of haemoglobin in the patient's faeces, alongside the usual diagnostic work done by GPs could rule out nearly a third of patients from requiring an endoscopy to check for (serious bowel disease)."
The study looked at results for 810 patients from 266 GP practices in the Netherlands. Out of the 810 patients referred for an endoscopy, 669 were found to have no serious bowel disease.
The researchers found that about 30% of these patients could have been prevented from having an endoscopy. However, the researchers did point out that there was a small risk some patients with bowel cancer could be missed by using FIT.
The authors said careful monitoring for persistent symptoms would be needed, and may result in a delay in diagnosis for some patients. The FIT test is being rolled out in the UK over the next few years and is much simpler than the current fecal occult blood (Fob) test.The Fob test involves collecting six small samples of feces over a few days and posting them to a screening center.
The FIT test is much easier to use, requiring just one sample that is collected with a brush and then put into a small tube of liquid. It is also more accurate and experts hope it will lead to more cases of bowel cancer being detected.
Dr Anne Mackie, director of programmes for the UK National Screening Committee, managed by Public Health England, said, "The new FIT test, which will be rolled out in the English Bowel Cancer Screening Programme over the next few years, will make it easier for people to get checked for risk of bowel cancer - as early diagnosis and treatment can save lives.
"PHE has already started looking into the logistics of introducing FIT and is keen to see this new improved kit fully available as soon as possible."
The study is published in the journal BMC Medicine.
Source: Medindia
Bowel Cancer Rates on Rise
Among men, bowel cancer rates have increased by 29 percent and among women only by about six percent, states report.
Advertisement
 Doubts Casts on Repeat Bowel Cancer SurgeryThe online journal BMJ Open has published the trial today | Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
Chronotherapy (the sleep-wake cycle) is observed as a valuable alternative treatment in cancer diagnosis and treatment.
A nanoengineering platform targets neutrophils, the white blood cells without killing pancreatic cancer cells paving the way for effective treatments.
The survival rates between lobectomy and wedge resection surgical procedures were found to be the same among lung cancer patients.
The mechanism by which the kinases cause inflammation has been discovered by scientists.
Pancreatic cancer cases are on the rise. The biomarker approach could reduce the chance of developing pancreatic cancer.